Overview PERmixon® in LUTS Evaluation Study (PERLES) Status: Completed Trial end date: 2016-06-01 Target enrollment: Participant gender: Summary The aim of this study is to support the efficacy of Permixon 160 mg b.i.d. in treating subjects with symptomatic Benign Prostatic Hyperplasia (BPH), compared to placebo, using Tamsulosine LP 0.4 mg as a reference treatment. Phase: Phase 4 Details Lead Sponsor: Pierre Fabre MedicamentTreatments: PermixonSaw palmetto extractTamsulosin